Therefore, AUF1-targeting activators may promote cancers in which the mTORC2-AKT pathway is upregulated, and it is valuable to further investigate whether they can be combined with Torin-1 drugs to treat such cancers [77]. The gene discussed is AKT1; the disease is cancer.